Antibodies against infliximab are associated with increased risk of anti-adalimumab antibody development in patients with inflammatory bowel disease

被引：1
|
作者：
Frederiksen, M. T. [1 ]
Ainsworth, M. A. [1 ]
Brynskov, J. [1 ]
Thomsen, O. O. [1 ]
Bendtzen, K. [2 ]
Steenholdt, C. [1 ]
机构：
[1] Herlev Univ Hosp, Dept Gastroenterol, DK-2730 Herlev, Denmark
[2] Univ Copenhagen Hosp, Rigshosp, Inst Inflammat Res, DK-2100 Copenhagen, Denmark
来源：
JOURNAL OF CROHNS & COLITIS | 2014年 / 8卷
关键词：
D O I：
10.1016/S1873-9946(14)60678-4
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
P558
引用
收藏
页码：S300 / S300
页数：1
相关论文
共 50 条
  • [1] Antibodies Against Infliximab Are Associated With Increased Risk of Anti-Adalimumab Antibody Development in Patients With Inflammatory Bowel Disease
    Frederiksen, Madeline T.
    Ainsworth, Mark A.
    Brynskov, Jorn
    Thomsen, Ole
    Bendtzen, Klaus
    Steenholdt, Casper
    [J]. GASTROENTEROLOGY, 2014, 146 (05) : S238 - S238
  • [2] Interactions Between Thiopurine Metabolites and Adalimumab and Anti-adalimumab Antibodies in Inflammatory Bowel Disease
    Holmstrom, Rikke
    Mogensen, Ditte
    Brynskov, Jorn
    Ainsworth, Mark
    Nersting, Jacob
    Schmiegelow, Kjeld
    Steenholdt, Casper
    [J]. INFLAMMATORY BOWEL DISEASES, 2017, 23 : S43 - S43
  • [3] Obesity is associated with a higher risk of immunogenicity to adalimumab, but not to infliximab in patients with Inflammatory Bowel Disease
    Mahmoud, R.
    Schultheiss, J.
    Louwers, J.
    van der Kaaij, M.
    van Hellemondt, B.
    Mahmmod, N.
    van Boeckel, P.
    Jharap, B.
    Fidder, H.
    Oldenburg, B.
    [J]. JOURNAL OF CROHNS & COLITIS, 2021, 15 : S420 - S421
  • [4] A case of Crohn’s disease that developed anti-infliximab and anti-adalimumab antibodies
    Takahashi K.
    Fujimoto T.
    Shioya M.
    Nishida A.
    Bamba S.
    Inatomi O.
    Imaeda H.
    Kitoh K.
    Andoh A.
    [J]. Clinical Journal of Gastroenterology, 2015, 8 (2) : 88 - 91
  • [5] Suppression of anti-drug antibodies to infliximab or adalimumab with the addition of an immunomodulator in patients with inflammatory bowel disease
    Strik, A. S.
    van den Brink, G. R.
    Ponsioen, C.
    Mathot, R.
    Loewenberg, M.
    D'Haens, G. R.
    [J]. ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2017, 45 (08) : 1128 - 1134
  • [6] Interactions Between Thiopurine Metabolites, Adalimumab, and Antibodies Against Adalimumab in Previously Infliximab-Treated Patients with Inflammatory Bowel Disease
    Holmstrom, Rikke B.
    Mogensen, Ditte V.
    Brynskov, Jorn
    Ainsworth, Mark A.
    Nersting, Jacob
    Schmiegelow, Kjeld
    Steenholdt, Casper
    [J]. DIGESTIVE DISEASES AND SCIENCES, 2018, 63 (06) : 1583 - 1591
  • [7] Interactions Between Thiopurine Metabolites, Adalimumab, and Antibodies Against Adalimumab in Previously Infliximab-Treated Patients with Inflammatory Bowel Disease
    Rikke B. Holmstrøm
    Ditte V. Mogensen
    Jørn Brynskov
    Mark A. Ainsworth
    Jacob Nersting
    Kjeld Schmiegelow
    Casper Steenholdt
    [J]. Digestive Diseases and Sciences, 2018, 63 : 1583 - 1591
  • [8] Anti-adalimumab Antibodies in Patients with Non-infectious Ocular Inflammatory Disease: A Case Series
    McKay, K. Matthew
    Apostolopoulos, Nicholas
    Chou, Brian
    Leveque, Thellea K.
    Van Gelder, Russell N.
    [J]. OCULAR IMMUNOLOGY AND INFLAMMATION, 2022, 30 (7-8) : 1721 - 1725
  • [9] Disappearance of anti-drug antibodies to infliximab and adalimumab after addition of an immunomodulator in patients with inflammatory bowel disease
    Strik, A.
    van den Brink, G.
    Ponsioen, C.
    Mathot, R.
    Lowenberg, M.
    D'Haens, G.
    [J]. JOURNAL OF CROHNS & COLITIS, 2016, 10 : S69 - S70
  • [10] Prior Antibodies to Infliximab or Adalimumab Are Related to Immunogenicity to Vedolizumab in Patients With Inflammatory Bowel Disease
    Papamichael, Konstantinos
    Vande Casteele, Niels
    Abraham, Bincy P.
    Ritter, Timothy
    Jain, Anjali
    Cheifetz, Adam S.
    [J]. CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, 2023, 21 (11) : 2978 - +
12345